Vitiligo-Like Depigmentation During Immunotherapy Associated with Improved Survival

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the Journal of Clinical Oncology, researchers in the Netherlands have found that although vitiligo-like depigmentation occurs only in a small number of patients with melanoma treated with immunotherapy, there is an evident survival benefit in these patients.

Vitiligo-like depigmentation in patients with melanoma was thought to be associated with more favorable clinical outcomes. Therefore, researchers sought to determine the cumulative incidence of vitiligo-like depigmentation and the prognostic value of vitiligo development on survival in patients with stage III to IV melanoma treated with immunotherapy.

Researchers identified 139 studies that included 139 treatment arms. Of those, 11 studied general immune stimulation, 84 studied vaccines, 28 were antibody-based, and 16 studied adoptive cell transfer. The studies included a total of 5,737 patients. Results showed the overall cumulative incidence of vitiligo was 3.4% (95% CI: 2.5 - 4.5%).

Researchers also found that vitiligo development was associated with progression-free survival (HR = 0.51; 95% CI: 0.32 - 0.82; P < 0.005) and overall survival (HR = 0.25; 95% CI: 0.10 - 0.61; P < 0.003).

The findings suggest that patients who developed vitiligo had two to four times less risk of disease progression and death compared with those who did not develop vitiligo.

Baseline a-fetoprotein levels may be a predictive marker for advanced hepatocellular carcinoma recei
Although vitiligo-like depigmentation occurs only in patients with melanoma treated with immunotherapy, there is an evident survival benefit.
The authors conducted a systematic review of patients with stage III to IV melanoma treated with immunotherapy to determine the cumulative incidence of vitiligo-like depigmentation and the prognostic value of vitiligo development on survival.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters